IMVT-1401, a fully human anti-FcRn antibody designed to be administered via subcutaneous injection, is the only anti-FcRn antibody known to be in clinical development for the treatment of GO Topline results from the ASCEND-GO 2 program are expected in early 2021...
GENFIT: Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without any modifications, based on the pre-planned...
With the advent of digital media, the ability to reach a wide audience has never been easier. A patient recruitment company isn’t limited to traditional methods, as digital platforms can be a vital tool when implemented to reach patients for future trials....
Vaccitech progresses clinical development of Universal Influenza A Vaccine (VTP-100) in Belgium and Australia and expects top-line data in early 2020 Vaccitech Ltd, a clinical-stage T cell immunotherapy company developing products to treat and prevent cancer and...
–RRx-001 led to an overall survival of 21.9 months and progression-free survival of 13 months– –Data presented at the Society for Neuro-Oncology annual meeting– LA JOLLA, CA, USA I November 25, 2019 I EpicentRx, Inc., a clinical cancer...
This is the world’s first IRB-approved clinical trial aimed at reversing aging by at least 20 years; it is also the world’s most expensive pay-to-play trial with a one million price tag to enroll. MANHATTAN, Kan., Nov. 21, 2019 /PRNewswire/ — Libella...
Email
Text